These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1631569)

  • 1. Kinetic considerations on the physiologic control of thrombin and factor Xa.
    Scully MF
    Semin Thromb Hemost; 1992; 18(2):218-23. PubMed ID: 1631569
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
    Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of molecular weight on the biological activity of heparin like sulphated hyaluronic acids.
    Barbucci R; Lamponi S; Magnani A; Renier D
    Biomaterials; 1998; 19(7-9):801-6. PubMed ID: 9663756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II.
    Tollefsen DM; Sugimori T; Maimone MM
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors.
    Thompson EA; Salem HH
    Thromb Haemost; 1987 Oct; 58(3):806-10. PubMed ID: 2829375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 16. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 17. [Inhibitors of the serine-proteases of coagulation with special reference to antithrombin III and heparin cofactor II].
    Fontcuberta J
    Sangre (Barc); 1985; 30(4-C):787-91. PubMed ID: 3841417
    [No Abstract]   [Full Text] [Related]  

  • 18. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anesthetic implications of the new anticoagulant and antiplatelet drugs.
    Vitin AA; Dembo G; Vater Y; Martay K; Azamfirei L; Ezri T
    J Clin Anesth; 2008 May; 20(3):228-37. PubMed ID: 18502371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.